Singapore’s Temasek Holdings joined a $150-million Series E funding round in Chinese biotech firm Innovent Biologics, Inc., according to a company announcement on Thursday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
